What is KeyCorp's Estimate for LAB Q1 Earnings?

Standard BioTools Inc. (NASDAQ:LAB - Free Report) - Investment analysts at KeyCorp issued their Q1 2025 earnings estimates for shares of Standard BioTools in a research note issued on Wednesday, February 26th. KeyCorp analyst P. Knight anticipates that the company will post earnings of ($0.06) per share for the quarter. KeyCorp currently has a "Sector Weight" rating on the stock. The consensus estimate for Standard BioTools' current full-year earnings is ($0.29) per share.

Standard BioTools Price Performance

NASDAQ LAB traded down $0.09 during trading hours on Monday, reaching $1.12. 781,983 shares of the stock traded hands, compared to its average volume of 2,114,631. The stock has a 50 day simple moving average of $1.55 and a two-hundred day simple moving average of $1.78. The company has a market cap of $415.07 million, a price-to-earnings ratio of -1.58 and a beta of 1.57. Standard BioTools has a 1 year low of $0.99 and a 1 year high of $3.04.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in Standard BioTools by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 6,975,221 shares of the company's stock worth $12,209,000 after purchasing an additional 25,504 shares in the last quarter. Hollow Brook Wealth Management LLC purchased a new stake in shares of Standard BioTools in the 3rd quarter worth about $10,679,000. State Street Corp lifted its position in Standard BioTools by 26.7% during the 3rd quarter. State Street Corp now owns 5,495,136 shares of the company's stock valued at $10,606,000 after acquiring an additional 1,157,984 shares during the period. Barclays PLC lifted its holdings in shares of Standard BioTools by 13.2% during the third quarter. Barclays PLC now owns 3,228,360 shares of the company's stock valued at $6,231,000 after purchasing an additional 377,195 shares during the last quarter. Finally, Mirabella Financial Services LLP bought a new position in shares of Standard BioTools during the 4th quarter valued at $5,478,000. Institutional investors own 53.74% of the company's stock.

Insiders Place Their Bets

In other Standard BioTools news, Director Casdin Partners Master Fund, L bought 4,820,959 shares of the business's stock in a transaction that occurred on Friday, February 28th. The shares were bought at an average cost of $1.06 per share, with a total value of $5,110,216.54. Following the completion of the purchase, the director now directly owns 58,846,780 shares of the company's stock, valued at $62,377,586.80. This trade represents a 8.92 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 53.10% of the stock is currently owned by insiders.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.